Press Release

HOLLYROCK MILLER MARKETING COMMUNICATIONS

For Immediate Release

Contact: Phil Farrelly, 973-376-7400, Ext. 202
Hudson Control Group
pfarrelly@hudsoncontrol.com

Hudson Control Group Enters Into OEM Agreement to Assemble AutoLoader System for Illumina

SPRINGFIELD, NJ-August 22, 2006--Hudson Control Group, Inc. has entered into a non-exclusive, worldwide OEM agreement with Illumina, Inc., under which Illumina markets Hudson's Platecrane EX Microplate Robot as Illumina's AutoLoader for their BeadArray readers. The AutoLoader provides walkaway freedom of operation for loading and scanning Illumina's Sentrix ® BeadChips. Configured to load single or dual BeadArray Readers, the AutoLoader offers the improved efficiency and decreased cost of continuous unattended operation.

According to Phil Farrelly, Hudson President and CEO, "Hudson is very pleased to be working with Illumina on their new Autoloader product line. Illumina's confidence in the Platecrane EX confirms Hudson's efforts to provide the most advanced yet rugged robotic technology available to research laboratories."

About Hudson Control Group:

Located in Springfield, New Jersey, Hudson Control Group is a leader in microplate automation, robotics and customized software-driven solutions.

The company works with customers in the drug discovery, high-throughput screening, proteomics and genomics markets to develop strategies that best meet their unique needs, whether for an integrated system of automated laboratory equipment or for automating a single instrument.

For more information, go to www.hudsoncontrol.com/platecraneex.html

About Illumina, Inc.:

Illumina (www.illumina.com; Nasdaq:ILMN;) develops and markets next-generation tools for the large-scale analysis of genetic variation and function. The Company's proprietary BeadArray technology -- used in leading genomics centers around the world -- provides the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine by correlating genetic variation and gene function with particular disease states, enhancing drug discovery, allowing diseases to be detected earlier and more specifically, and permitting better choices of drugs for individual patients. For more information on the Illumina AutoLoader, go to http://www.illumina.com/General/pdf/systems_AutoLoaderDatasheet.pdf